Total Funding
51
45
Total FundingSeries B raised
Growth Score
-5 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
65192
Axio is a medtech R&D and Manufacturing Company focused on Advanced surgical and woundcare products based on novel biomaterials.
- Leo Mavely: Founder & CEOPast Role: NirmaLabs, Incubatee
About the Company
Axio is a medtech R&D and Manufacturing Company focused on Advanced Surgical and wound care. Axio has the distinction to be the first company from India to get USFDA clearance for a woundcare/hemostat product. Controlling life threatening bleeding continues to be the major cause of death from traumatic injuries. Axiostat is its flagship
product developed to reduce the mortality due to traumatic bleeding. A CE approved product, Axiostat is based on a patented novel 100% chitosan platform and has variants catering to Emergency & Trauma, Military, Cardio-vascular and Dental applications.
